Surgery Partners Inc (SGRY) Expected to Post Quarterly Sales of $449.18 Million

Analysts predict that Surgery Partners Inc (NASDAQ:SGRY) will post sales of $449.18 million for the current quarter, according to Zacks. Four analysts have issued estimates for Surgery Partners’ earnings. The highest sales estimate is $451.52 million and the lowest is $448.00 million. Surgery Partners posted sales of $444.78 million during the same quarter last year, which suggests a positive year-over-year growth rate of 1%. The firm is expected to report its next earnings report on Thursday, August 8th.

On average, analysts expect that Surgery Partners will report full-year sales of $1.85 billion for the current fiscal year, with estimates ranging from $1.82 billion to $1.88 billion. For the next year, analysts anticipate that the company will post sales of $2.01 billion, with estimates ranging from $1.91 billion to $2.12 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Surgery Partners.

Surgery Partners (NASDAQ:SGRY) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.03). The business had revenue of $416.80 million during the quarter, compared to analysts’ expectations of $421.41 million. Surgery Partners had a negative return on equity of 4.01% and a negative net margin of 11.59%. The company’s quarterly revenue was up 1.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.26) EPS.

A number of research firms recently commented on SGRY. BidaskClub raised Surgery Partners from a “hold” rating to a “buy” rating in a research note on Thursday, February 7th. Stifel Nicolaus set a $12.00 target price on Surgery Partners and gave the company a “hold” rating in a research note on Wednesday, May 8th. Zacks Investment Research cut Surgery Partners from a “hold” rating to a “sell” rating in a research note on Wednesday, May 15th. Finally, ValuEngine cut Surgery Partners from a “buy” rating to a “hold” rating in a research note on Thursday, February 7th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. Surgery Partners has a consensus rating of “Hold” and a consensus price target of $17.60.

In related news, Director Adam T. Feinstein sold 7,865 shares of the stock in a transaction on Monday, May 20th. The stock was sold at an average price of $9.95, for a total value of $78,256.75. Following the transaction, the director now owns 8,895 shares of the company’s stock, valued at $88,505.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 8.20% of the stock is owned by corporate insiders.

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Surgery Partners by 1.2% during the third quarter. Vanguard Group Inc. now owns 1,566,343 shares of the company’s stock valued at $25,845,000 after buying an additional 18,336 shares during the last quarter. Vanguard Group Inc grew its stake in shares of Surgery Partners by 1.2% during the third quarter. Vanguard Group Inc now owns 1,566,343 shares of the company’s stock valued at $25,845,000 after buying an additional 18,336 shares during the last quarter. BlackRock Inc. grew its stake in shares of Surgery Partners by 16.9% during the fourth quarter. BlackRock Inc. now owns 1,452,957 shares of the company’s stock valued at $14,225,000 after buying an additional 209,539 shares during the last quarter. Elk Creek Partners LLC grew its stake in shares of Surgery Partners by 5.3% during the first quarter. Elk Creek Partners LLC now owns 1,373,263 shares of the company’s stock valued at $15,490,000 after buying an additional 69,669 shares during the last quarter. Finally, Royce & Associates LP grew its stake in shares of Surgery Partners by 1.2% during the first quarter. Royce & Associates LP now owns 1,058,381 shares of the company’s stock valued at $11,939,000 after buying an additional 12,500 shares during the last quarter. 96.33% of the stock is currently owned by hedge funds and other institutional investors.

SGRY traded up $0.28 during trading on Friday, reaching $10.28. The stock had a trading volume of 527,139 shares, compared to its average volume of 248,151. The stock has a market cap of $498.73 million, a PE ratio of -4.20 and a beta of 2.47. The company has a quick ratio of 1.56, a current ratio of 1.49 and a debt-to-equity ratio of 2.20. Surgery Partners has a one year low of $9.14 and a one year high of $18.70.

Surgery Partners Company Profile

Surgery Partners, Inc, through its subsidiaries, owns and operates a network of surgical facilities and related services in the United States. The company operates through three segments: Surgical Facility Services, Ancillary Services, and Optical Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management.

Further Reading: What is the Bid-Ask Spread?

Get a free copy of the Zacks research report on Surgery Partners (SGRY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.